Goldman Sachs downgraded CME Group to Sell from Neutral with a $195 price target. The analyst believes CME was over-earning in 2022 and 2023 amid record spike in interest rate volatility, above-typical pricing increases, and higher earnings on customers’ cash collateral resulting in a high-teen earnings growth. The firm expects the company’s earnings growth to slow down to low-single-digits through 2026 on the back of normalization in interest rates volatility, compression in interest income generated from cash collateral balances, and competitive dynamics in equities and energy franchises where CME has been losing share.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CME: